Significant tacrolimus and dronedarone interaction in a kidney transplant recipient

Transplantation

Volumn 98, Issue 4, 2014, Pages e33-e34

  Marin Casino, Mónica ^a   Pérez Sáez, Maria J ^a   Crespo, Marta ^a   Echeverría, Daniel ^a   Mir, Marisa ^a   Pascual, Julio ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BASILIXIMAB; CIPROFLOXACIN; CORTICOSTEROID; CREATININE; DRONEDARONE; MYCOPHENOLIC ACID; TACROLIMUS; ANTIARRHYTHMIC AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ADULT; CASE REPORT; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HOSPITAL READMISSION; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; IMMUNOSUPPRESSIVE TREATMENT; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LETTER; MALE; MIDDLE AGED; NAUSEA; POSTOPERATIVE CARE; PRIORITY JOURNAL; QT INTERVAL; RETREATMENT; SINUS RHYTHM; TREMOR; URINARY TRACT INFECTION; DRUG EFFECT; DRUG INTERACTION; ELECTROCARDIOGRAPHY;

AMIODARONE; ANTI-ARRHYTHMIA AGENTS; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; TACROLIMUS;

EID: 84908003921     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000280     Document Type: Letter

References (13)

1. Pamukcu B, Lip GY. Dronedarone as a new treatment option for atrial fibrillation patients: pharmacokinetics, pharmacodynamics and clinical practice. Expert Opin Pharmacother 2011; 12: 131.
2. Adlan AM, Lip GY. Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation. Drug Saf. 2013; 36: 93.
3. Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amioda-rone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010; 21: 597.
4. Ozkanlar Y, Nishijima Y, da Cunha D, et al. Acute effects of tacrolimus (FK506) on left ventricular mechanics. Pharmacol Res 2005; 52: 307.
5. Gonzalez JE, Sauer WH, Krantz MJ. Ventricular ectopy and QTc-interval prolongation associated with dronedarone therapy. Pharmacotherapy 2013; 33: e179.
6. Scott LJ, McKeage K, Keam SJ, et al. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247.
7. Staatz CE, Tett SE. Clinical pharmacokinet-ics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 2004; 43: 623.
8. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997; 27: 201.
9. Schafer JA, Kjesbo NK, Gleason PP. Drone-darone: current evidence and future questions. Cardiovasc Ther 2010; 28: 38.
10. Kisters K, Cziborra M, Funke C, et al. Amiodarone-tacrolimus interaction in kid-ne y transplantation. Clin Nephrol 2008; 70: 563.
11. Burger CI, Clase CM, Gangji AS. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. Transplantation 2010; 89: 1166.
12. Tichy EM, Medwid AJ, Mills EA, et al. Significant sirolimus and dronedarone interaction in a kidney transplant recipient. Ann Pharmacother 2010; 44: 1338.
13. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674.